LT3001 Stroke Drug Shows Phase 2 Functional Gains
Taipei, Taiwan — February 6, 2026 Lumosa Therapeutics has announced positive Phase 2 clinical trial outcomes for LT3001 (odatroltide),...
drug development
Advertisement
Janux and BMS Partner on Tumor-Activated Cancer Therapy
SAN DIEGO, January 22, 2026 — Janux Therapeutics announced a collaboration and exclusive worldwide license agreement with Bristol Myers...
Nxera Reports Positive Phase 3 Results for Daridorexant
TOKYO, Japan and CAMBRIDGE, United Kingdom | January 19, 2026 — Nxera Pharma Co., Ltd. announced positive top-line results...
Lilly to Acquire Ventyx to Expand Oral Inflammation Therapies
INDIANAPOLIS | January 7, 2026 — Eli Lilly and Company has announced an agreement to acquire Ventyx Biosciences, a...
Atom Therapeutics Advances ABP-745 into Phase 2 ASCVD Trial
December 16, 2025 – Cambridge, Massachusetts — Atom Therapeutics has announced the initiation of a multi-regional Phase 2 clinical...
Advertisements
Morphocell Secures $50M to Advance Stem-Cell Liver Therapy
Laval, Québec, December 1, 2025 — Morphocell Technologies has announced the successful completion of its US$50 million Series A...
Can-Fite Highlights Major Progress Across Late-Stage Drug Pipeline
Ramat Gan, Israel, November 26, 2025 — Can-Fite BioPharma has announced key updates across its advanced-stage clinical pipeline ahead...
Pfizer Finalizes Metsera Acquisition to Expand Obesity Pipeline
NEW YORK, NY — November 14, 2025 — Pfizer announced it has completed its acquisition of Metsera, Inc., strengthening...
Day One Biopharma Acquires Mersana to Advance ADC Pipeline
BRISBANE, CA – November 13, 2025 — Day One Biopharmaceuticals announced a definitive agreement to acquire Mersana Therapeutics in...
Immedica Submits NDS for Loargys® (pegzilarginase) in Canada
Stockholm, Sweden – October 31, 2025 — Immedica Pharma has announced that its New Drug Submission (NDS) for Loargys®...
Advertisement
